Evidence map›Paper›PMID 24440821›Full record

ReviewBiochimica et biophysica acta2014

Chemical modulation of glycerolipid signaling and metabolic pathways.

Sarah A Scott, Thomas P Mathews, Pavlina T Ivanova, Craig W Lindsley, H Alex Brown

Abstract readReview
In one paragraph

Review in Biochimica et biophysica acta, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed.

  1. A targeted lipidomics workflow for high-throughput phenotyping and mechanism-based in vitro hepatotoxicity studies.Toxicology in vitro : an international journal published in association with BIBRA · 2026
    Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Review
  15. Review
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Sarah A ScottDepartment of Pharmacology, Vanderbilt University Medical Center, Nashville, TN 37232, USA.
Thomas P MathewsDepartment of Pharmacology, Vanderbilt University Medical Center, Nashville, TN 37232, USA; Vanderbilt Center for Neuroscience Drug Discovery, Vanderbilt University Medical Center, Nashville, TN 37232, USA.
Pavlina T IvanovaDepartment of Pharmacology, Vanderbilt University Medical Center, Nashville, TN 37232, USA.
Craig W LindsleyDepartment of Pharmacology, Vanderbilt University Medical Center, Nashville, TN 37232, USA; Vanderbilt Center for Neuroscience Drug Discovery, Vanderbilt University Medical Center, Nashville, TN 37232, USA; Department of Chemistry, Vanderbilt University, Nashville, TN 37235, USA; Vanderbilt Institute of Chemical Biology, Vanderbilt University, Nashville, TN 37235, USA.
H Alex BrownDepartment of Pharmacology, Vanderbilt University Medical Center, Nashville, TN 37232, USA; Department of Biochemistry, Vanderbilt University Medical Center, Nashville, TN 37232, USA; Vanderbilt Institute of Chemical Biology, Vanderbilt University, Nashville, TN 37235, USA. Electronic address: alex.brown@vanderbilt.edu.

Funding

The Vanderbilt Specialized Chemistry Center for Accelerated Probe DevelopmentU54MH084659 · NIMH · VANDERBILT UNIVERSITY · PI MEILER, JENS · 2008 to 2013
$24.1M
Protein Adducts and Proteome Profiles in Oxidative StressP01ES013125 · NIEHS · VANDERBILT UNIVERSITY · PI PORTER, NED ALLEN · 2005 to 2012
$12.6M
MULTIDISCIPLINARY BASIC RESEARCH TRAINING IN CANCERT32CA009592 · NCI · VANDERBILT UNIVERSITY · PI Justin M Balko, Julie A Rhoades (Sterling) · 1987 to 2026
$10.4M
SLOS and Neuronal Oxidative StressR01HD064727 · NICHD · VANDERBILT UNIVERSITY · PI PORTER, NED ALLEN · 2010 to 2020
$3.7M
Postdoctoral Training in CNS Drug Discovery ResearchT32MH093366 · NIMH · VANDERBILT UNIVERSITY · PI CONN, P JEFFREY · 2011 to 2015
$1.0M
NCI NIH HHS T32 CA009592NICHD NIH HHS R01 HD064727NIEHS NIH HHS P01 ES013125NIEHS NIH HHS P01-ES013125NIMH NIH HHS T32 MH093366NIMH NIH HHS U54 MH084659
6 · The paper itself

Abstract

Thirty years ago, glycerolipids captured the attention of biochemical researchers as novel cellular signaling entities. We now recognize that these biomolecules occupy signaling nodes critical to a number of physiological and pathological processes. Thus, glycerolipid-metabolizing enzymes present attractive targets for new therapies. A number of fields-ranging from neuroscience and cancer to diabetes and obesity-have elucidated the signaling properties of glycerolipids. The biochemical literature teems with newly emerging small molecule inhibitors capable of manipulating glycerolipid metabolism and signaling. This ever-expanding pool of chemical modulators appears daunting to those interested in exploiting glycerolipid-signaling pathways in their model system of choice. This review distills the current body of literature surrounding glycerolipid metabolism into a more approachable format, facilitating the application of small molecule inhibitors to novel systems. This article is part of a Special Issue entitled Tools to study lipid functions.

Indexed as

Signal TransductionAcyltransferasesGlycerolLipaseLipidsPhospholipasesPhosphoric Monoester HydrolasesPhosphotransferasesAcyltransferasesGlycerolLipaseLipidsPhospholipasesPhosphoric Monoester HydrolasesPhosphotransferasesAutotaxinFatty acyltransferaseGlycerolipidInhibitorLipaseLipid kinaseLipinMetabolismPhospholipase

Identifiers

PMID24440821
PMCPMC4069240

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.